Share Email Print
cover

Proceedings Paper

In vivo uptake and photodynamic activity of porphycenes
Author(s): Sol Kimel; Varda Gottfried; Ronit Davidi; Claudia Averbuj
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Novel porphyrinoid photosensitizers are currently being considered for use in photodynamic therapy (PDT) of cancer. This class of sensitizers combines high absorption characteristics at the therapeutic wavelengths ((lambda) > 600 nm) and good tumor targeting properties. We have investigated the in-vivo uptake and photodynamic damage of several porphycenes. Our model system was the chick chorioallantoic membrane (CAM) which we have adapted for use in PDT studies. The CAM assay allows fast screening of novel drugs and obtaining statistically relevant results with minute quantities of the drug. Sensitizers were `trapped' in EPC (egg phosphatidylcholine) or in DPPC (dipalmitoyl phosphatidylcholine); their efficiencies were independent of the vehicle used for application of the sensitizer. The efficiencies of various porphycenes in PDT, as a function of drug and light dose, compare well with those of standard porphyrins and phthalocyanines.

Paper Details

Date Published: 1 March 1994
PDF: 7 pages
Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); doi: 10.1117/12.168654
Show Author Affiliations
Sol Kimel, Technion--Israel Institute of Technology (Israel)
Varda Gottfried, Technion--Israel Institute of Technology (Israel)
Ronit Davidi, Technion--Israel Institute of Technology (Israel)
Claudia Averbuj, Technion--Israel Institute of Technology (Israel)


Published in SPIE Proceedings Vol. 2078:
Photodynamic Therapy of Cancer
Giulio Jori; Johan Moan; Willem M. Star, Editor(s)

© SPIE. Terms of Use
Back to Top